



## **Bausch + Lomb Receives Health Canada Approval for Soothe® Antibiotic Drops**

VAUGHAN, Ontario, Oct. 22, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Health Canada has approved Soothe Antibiotic Drops, an over-the-counter drop to treat external infections of the eye and ear, such as bacterial conjunctivitis (pink eye) and swimmer’s ear<sup>1</sup>.

“There is growing demand for over-the-counter products that effectively address common eye and ear infections,” said John Ferris, executive vice president, Consumer, Bausch + Lomb. “Soothe Antibiotic Drops will provide Canadian consumers with a new convenient and effective option.”

Soothe Antibiotic Drops are approved for use by adults and children\* six years of age and older. Building on the company’s Soothe brand of dry eye and allergy products, the drops will be packaged in a convenient 10 mL easy-squeeze bottle and located in the eye care aisle at most major Canadian retailers starting in June 2025.

“Soothe Antibiotic Drops offer consumers and clinicians a single treatment option that is conveniently available over the counter without a prescription. Once available, it will be a valuable addition to a pharmacist’s toolkit,” **said Dharmesh Vaghela, Bsc., pharmacist, Mississauga, Ontario.**

###

## **About Bausch + Lomb**

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit [www.bausch.com](http://www.bausch.com) and connect with us on [X](#), [LinkedIn](#), [Facebook](#) and [Instagram](#).

## **Forward-looking Statements**

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

*1 Always read and follow the label to know if this product is right for you.*

*\*A doctor should be consulted prior to use of the drops in children.*

© 2024 Bausch + Lomb.

SOA.0001.USA.24

## **Media Contact:**

Kristy Marks

[kristy.marks@bausch.com](mailto:kristy.marks@bausch.com)

(908) 927-0683

**Investor Contact:**

George Gadkowski

[george.gadkowski@bausch.com](mailto:george.gadkowski@bausch.com)

(877) 354-3705 (toll free)

(908) 927-0735